1 / 17

cardiovascular outcome in trial of new antidiabetic drugs

Effect of new antidiabetic drugs in cardiovascular mortality and morbidity

30947
Download Presentation

cardiovascular outcome in trial of new antidiabetic drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CARDIOVASCULAR OUTCOME IN TRIAL OF NEW ANTIDIABETIC DRUGS PROFESSOR / MOHAMMED AHMED BAMASHMOOS

  2. RISK FACTORS OF CVD IN TYPE 2-DIABETIC 1- Hyperglycemia ; any increase in HbA1C by 1 is associated with increase in CV mortality and morbidity by 11% - 16% 2- hypoglycemia ; it leads to - increased inflammation as CRP - endothelial dysfunction - sympatho adrenal response - increased adrenaline 3- weight gain and obesity ; ● - hypertension ● - dyslipidemia ● - IR ● - increased plasma volume ● - increased inflammation ● - ● ● ● ● ● ●

  3. 4- insulin resistance lead to ; - hypertension - atherosclerosis - dyslipidemia - endothelial dysfunction - hyperuricemia 5- endothelial dysfunction 6- inflammation 7- hyper coagulation ● ● ● ● ● ● ● ● ●

  4. PATHOGENESIS

  5. LIST OF NOVEL ANTIDIABETIC DRUGS 1- metformin 2- SGLT type 2 inhibitor 3- dipeptidyl peptidase type 4 inhibitor 4- GLP1 receptor agonist ● ● ● ●

  6. Metformin SGLT type 2 GLP1 DPP HbA1C reduction 1-1.5 0.2-0.8 0.5-1.4 0.5-0.8 Risk of hypoglycemia Neutral N N N Weight changes Neutral or gradual decrease Decrease by 3kg in the first year 6.5 at 40 weeks of treatment increase HDL , decrease total cholesterol , decrease LDL, VLDL, Increase HDL , decrease cholesterol , TG Effect in lipid Increase HDL Decrease Effect in IR Improve insulin sensitivity Decrease IR by decreasing glucotoxicity Decrease IR Decrease Effect in BP Decrease secondary to decrease IR Decrease BP Decrease BP, HR Decrease BP, HR Effect in endothelial function Improve Improve vascular function Enhance function Enhance function Decrease proinflammatory cytokine Inflammatory effect Decrease Decrease Decrease decrease PAI type 1. increase tissue plasminogen activator , decrease platelets aggregation and adhesion ) Effect in coagulopathy

  7. 3- GLP1 RECEPTOR AGONIST

  8. 4- DIPEPTIDYL PEPTIDASE TYPE 4 INHIBITOR

  9. /

More Related